A venture capital firm based in the Benelux region is focused on identifying and investing in promising European companies. The firm generally invests from the very early stages from Seed to Series A and often acts as the first institutional investor, but also reserves 1/3 of the fund to more late-stage opportunities as well. The firm could invest as little as $200K or up to $3M in a first investment round, depending on the company’s current stage of development. The firm seeks to invest in companies that have a presence in Europe.

The firm invests broadly across therapeutics, diagnostics, and agriculture, but does not invest in medical devices, healthcare IT, or bioinformatics. The is open to all different types of technologies and indications.

The firm can act as either a lead or co-investor. In cases where the firm acts as the first institutional investor, the firm will seek board representation and take an active role in helping the company grow.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in Taiwan invests in breakthrough technologies changing healthcare. The firm invests from seed-Series A. The fund’s LP’s include groups in the healthcare sector.

The firm invests in early stage life science startups with a focus on breakthrough technologies and sciences in healthcare. This includes genomic and synthetic biology technologies, digital health, ML/AI, therapeutics and diagnostics. The firm focuses on pre-IND assets in therapeutics. For technologies regulated as medical devices, the firm focuses on smart medical devices in the pre-commercial stage.

The firm’s partners have a strong clinical perspective; the firm has the capability to help portfolio companies develop clinical resources, and has helped academic scientists form companies to commercialize their discoveries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A subsidiary of a company that is sponsored by family offices in China is focused on research and distribution of class 2 and 3 medical devices in China, and is one of the major distributors for some of the largest multinational companies. Having offices in both USA and China, the firm has invested in companies that are based in greater Boston area, Los Angeles as well as Canada. The firm has a fund size of $30M, and the typical allocation ranges from $0.5M – $1M, with no specific limit. The firm has invested over 10 companies by now and will continue to expand its portfolio.

The firm is open to therapeutics and medical device companies, but is most interested in in-vitro diagnostic technologies. The firm is looking for companies that are in development or in the pre-clinical stage. The firm mostly invests in seed round but will invest up to pre-A. The firm is also interested in in-licensing opportunities in China as well.

The firm invests globally and does not have specific requirements regarding companies or their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage venture fund based in the USA generally makes equity investments in Healthcare IT and Pharma IT companies at growth stage. The typical investment size ranges from $1 million to $3 million. The firm focuses on companies based in the mid-Atlantic region of the USA.

The firm is currently looking for new opportunities in the Healthcare IT and Pharma IT sectors. The firm will not consider devices or biotech companies. The firm typically invests in companies that have started to generate revenues.

The firm focuses on private companies with between $1 million to $3 million in revenue. The firm prefers investments in companies with a strong management team and significant growth potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment company with base operations in China manages a￥3000M fund. The typical allocation size of the firm ranges from ￥50M to ￥100M (~$7 to 14M USD). The firm is generally interested in companies in therapeutics, medical devices, diagnostics, and healthcare IT areas.

The firm is interested in the medical device, diagnostics, and Healthcare IT companies. Within the therapeutics sector, the firm will mainly look at CRO and CDMO companies and it prefers companies with unique R&D platforms. The firm will look at companies that are in development and it is most interested in companies that are closed to commercialize or are already on the market. The firm prefers to invest in early-stage companies that are FDA/CE/NMPA approved or are closed to getting NMPA approval. The firm is willing to help its portfolio companies to expand their commercialization in Chinese market.

The firm prefers companies from China, but will also invest in foreign companies with China angles or China market or those who have branches in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family-run investment and commercialization vehicle invests in early-stage life science and technologies. The group is flexible in terms of deal structure with past investments ranging from minority commitments in a funding round to in-licensing entire therapeutic programs.

The firm specializes in therapeutic opportunities and has a particular focus on rare diseases. The group is most interested in indications where the pathophysiology is well-understood, the developmental pathway is straight-forward, and there is a clear unmet medical need. Opportunities that are de-risked in some way, such as reformulation or repurposing plays, are also considered attractive.

The firm has a strong preference for experienced management teams with proven tracks records of driving value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Taiwan solely invests in early stage medical technology ventures. The firm currently manages a USD 100 million fund. The firm focuses on Series A and B rounds and looks to allocate USD 500K to 3 million per round with reserved follow-on investments. The firm will target companies in Taiwan, Israel, and the US. The firm is actively seeking new investments.

The firm looks to invest in innovative medical devices. The firm seeks breakthrough products that are clearly differentiated and superior to existing products. The firm is opportunistic in terms of subsectors and will consider devices in Class I, II, and III. The firm is indication agnostic but only seeks large market opportunities of at least $500 million in targeted annual revenue.

The firm seeks a strong and experienced management team and typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.